CompletedNot Applicable

Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin

Egypt180 participantsStarted 2022-10-01

Plain-language summary

Ovarian hyperstimulation syndrome is a potentially fatal iatrogenic condition. This syndrome is characterized by a sudden increase of the vascular permeability which results in the development of a massive extravascular exudate in the peritoneal cavity, pleural, pericardium causing ascites, pleural and pericardial effusion. Severe forms are also accompanied by electrolyte disturbances and cardiopulmonary, hepatic, renal, and hemoconcentration associated with increased thromboembolic risk. This syndrome is avoidable by the judicious use of gonadotropins and careful monitoring of stimulation regimens.

Who can participate

Age range23 Years – 39 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * High risk patient for OHSS is defined as previous history of OHSS or \> 24 antral follicles of the ovaries on base line ultrasound (polycystic ovary) * During ovarian stimulation-increased number of small follicles (8-12 mm) * High AMH * Rapidly rising serum E2 * High serum E2 at hCG trigger (\>3000 pg/ ml) or presence of \> 20 follicles on the day of retrieval, by ultrasound examination or \>20 oocytes retrieved Exclusion Criteria: * patients with endocrine disorder e.g diabetes mellitus, Cushing's disease, and congenital adrenal hyperplasia, * Patients with hypertension, * Patients systemic disease e.g asthma, collagen vascular disease, hypercholesterolemia and sickle cell anemia.

What they're measuring

the incidence rate of moderate to severe OHSS.

Timeframe: 3 months

Trial details

NCT IDNCT06333691

SponsorMinia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-02-01

View on ClinicalTrials.gov More Ovarian Hyperstimulation Syndrome trials